Skip to main content

Table 2 Utilities and costs associated with adverse events

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Adverse event (grade 3–4) Utility decrement Reference Cost, GBP Reference
Nausea 0.05 [22] 1.00 Assumedb
Vomiting 0.05 [22] 1.00 Assumedb
Diarrhea 0.05 [22] 1.00 Assumedb
Abdominal pain 0.07 [23] 1.00 Assumedb
Thrombocytopenia 0.11 [24] 84.22 [25]
Lymphopenia 0.11 Assumeda 1.00 [26]
Leukopenia 0.11 Assumeda 160.66 [28]
Stomatitis 0.11 Assumeda 385.17 [27]
Fatigue 0.20 [20] 1.00 Assumedb
Infections 0.11 Assumeda 385.17 Assumedc
Asthenia 0.20 Assumeda 1.00 Assumedb
Anemia 0.12 [20] 375.00 [28]
Pyrexia 0.11 Assumeda 32.60 [27]
Hyperglycemia 0.11 Assumeda 385.17 Assumedc
Neutropenia 0.09 [22] 160.66 [28]
Hypertension 0.11 Assumeda 16.34 [27]
Musculoskeletal pain 0.11 Assumeda 385.17 Assumedc
Flushing 0.11 Assumeda 1.00 Assumedb
Decreased appetite 0.20 Assumed equal to fatigue 1.00 Assumedb
  1. aAssumed to be equal to worst disutility in line with NICE TA306 [21]
  2. bAssumed, does not have a notable impact on NHS resources at a national level, therefore assumed to be GBP 1.00
  3. cNo specific data available; assumed to be equal to the highest adverse event cost